Metamark Genetics, Inc., a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that effective May 25, 2016, the Company has signed an agreement with Anthem Blue Cross Blue Shield (BCBS) of Georgia to provide its members with in-network access to Metamark's comprehensive suite of urology specialized diagnostic offerings.

"Metamark is making important strides in our mission to be the leading provider of essential, decision-making information to urologists and their patients throughout the complete prostate cancer care continuum," said Jerry Williamson, president and chief executive officer. "We're very pleased with our new agreement with Anthem BCBS of Georgia, which expands the availability of our innovative diagnostic and prognostic testing. There is a growing recognition among payers nationwide of the benefits from our distinctive approach to delivering critical information to enable more informed and personalized treatment decisions."

Metamark has previously announced in-network agreements with additional large BCBS plans, and also has agreements in place with the largest PPO networks in the country.

About Metamark® 

Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.

For more information, please visit the company's website: www.metamarkgenetics.com.